NOVARTIS AG (NVS)
Health Care · Major Pharmaceutical Manufacturers · NYSE
Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
What NOVARTIS AG does
Novartis AG is a global healthcare company that focuses on the research, development, and manufacturing of innovative medicines. The company operates through several key therapeutic areas including oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic diseases. It leverages advanced technology platforms to address high unmet medical needs and improve patient outcomes globally.
Recent developments
Novartis announced in September 2026 that its Phase III HARBOR study for del-desiran in myotonic dystrophy type 1 did not meet its primary endpoint, though the company continues to analyze the dataset. Additionally, the company is advancing its neuromuscular pipeline with FDA priority review for del-zota in Duchenne muscular dystrophy.
From NOVARTIS AG's filing of 2026-09-08.
Themes: oncology, immunology, neuroscience / neurology, cardiovascular, renal and metabolic diseases (CRM), neuromuscular diseases, biotechnology / biologic medicines, radioligand therapy, AI in drug development
Fundamentals
- Price$153.64 as of 2026-10-20 close
- Market cap$286.6B market cap from Nasdaq, 2026-10-20
- 1-year return+16.6% 2025-10-20 close $131.79 → 2026-10-20 close $153.64
- P/En/a not reported by our data source
- ROE+30.0% FY2025, SEC XBRL
- ROICn/a No figure: it does not file US-GAAP statements with the SEC.
- Debt / equityn/a No figure: it does not file US-GAAP statements with the SEC.
- Beta0.22 as of 2026-09-03
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
Dividend: yield +3.4%; pays a dividend.
How NVS compares in its sector
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- indicated dividend yieldtop 10% 63 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, NVS's dividend was covered by reported results (earnings payout 56%, free-cash-flow payout 44%). This describes past coverage, not a forecast.
- Earnings payout56% dividends / net income
- Free-cash-flow payout44% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How NOVARTIS AG looks technically
NOVARTIS AG (NVS) is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-09-04, pushing above its recent trading range.
Trend
9
| Distance from the 200-day | it is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $148.06 | $148.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $151.15 | $151.15 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 139.31. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal | 13 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.6% above | +1.6% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 16.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 66.9 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($139.31 to $153.68) — its "stochastic" reading is 100 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $170.46 | $170.46 |
|---|---|---|
| From the 52-week high | it is 9.9% below its 52-week high (its highest price of the past year) | -9.9% |
| Above the 52-week low | it is 26.4% above its 52-week low (its lowest price of the past year) | +26.4% |
| Below the 52-week high | it is 9.9% below its highest point of the past year | 9.9% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-04, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 28 trading days ago | 28 sessions |
| All-time high | its highest closing price on record is $170.46 (set on 2026-02-27) | $170.46 |
| Given back of the 52-week move | over the past year its closes ranged ($121.80 to $168.62), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $138.19 to $139.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.0% |
| From the all-time high | it is 9.9% below its all-time high | -9.9% |
| Nearest price level | it is sitting right on a support level at $153.19 — a price it turned at four times since 2026-01-27, most recently on 2026-08-04. Since 2024-10-21 it has 15 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $23.24 (set on 1997-01-21) | $23.24 |
| Above the all-time low | it is 561.1% above its all-time low | +561.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 80% of the past ~6 months) | 80th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.72 between its high and its low — about 1.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.72 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $137.66 and $152.22 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $137.66 – $144.94 – $152.22 |
| Typical daily range (% of price) | its price moves about 1.8% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 1.8% |
| Stretch from the 200-day average | it is trading 0.9 daily ranges above its 200-day average price (1.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.08 toward sell |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 3 sessions ago and has not traded back through the level it left behind at 146.88 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 6.6% gap up opened on 2026-09-01 has been "filled" 30 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 30 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.5 percentage points (the stock gained 9.5% while the market gained 1.0%) | +8.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.9 percentage points (the stock gained 2.7% while the market gained 3.6%) | -0.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 6.8 percentage points (the stock gained 1.8% while the market gained 8.5%) | -6.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.0 percentage points (the stock gained 16.6% while the market gained 14.6%) | +2.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.9% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.0% of the share price, which is taken to mean a barrier that gives way easily. | +1.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $151.72 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | +1.3% |
|---|
Price levels it has turned at before
NVS last closed at $153.64 on 2026-10-20. Since 2024-10-21 it has turned at 15 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $153.19 | Support | 0.3% below the last close | turned there four times · 2026-01-27 to 2026-08-04 |
| $156.90 | Resistance | 2.1% above the last close | turned there twice · 2026-04-10 to 2026-08-11 |
| $149.31 | Support | 2.8% below the last close | turned there three times · 2026-04-07 to 2026-08-14 |
| $160.57 | Resistance | 4.5% above the last close | turned there three times · 2026-07-02 to 2026-08-19 |
| $146.32 | Support | 4.8% below the last close | turned there four times · 2026-01-14 to 2026-09-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $139.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-10-12.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Trading above the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Broke out to a new 20-day high · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.67 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$154.65 range $130.00 – $185.00; median $156.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NVS
- Consensus EPS estimate$2.24 next reporting period, as of 2026-10-18
- Estimate change, 30 days+$0.01164 (+0.5%) from $2.23, on 2026-09-13, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Generic and biosimilar competition affecting key product sales.","Clinical trial failures and regulatory approval delays or denials.","Litigation related to intellectual property and patent rights."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Most recent open-market transaction: 2020-06-30. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NVS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 12 matched disclosures for NVS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Short interest (FINRA)
NVS had 5,624,031 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for NVS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 5,624,031
- Prior settlement (shares) 5,195,725
- Reported change 8.24%
- Days to cover (reported) 2.93
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (ROG.SW)
- Pfizer (PFE)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
- Sanofi (SNY)
- Eli Lilly (LLY)
- Amgen (AMGN)
- Incyte (INCY)
- Genentech
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVS vs…
NOVARTIS AG is found in…
Frequently asked questions
What does NOVARTIS AG (NVS) do?
Novartis AG is a global healthcare company that focuses on the research, development, and manufacturing of innovative medicines. The company operates through several key therapeutic areas including oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic diseases. It leverages advanced technology platforms to address high unmet medical needs and improve patient outcomes globally.
What sector is NOVARTIS AG (NVS) in?
NOVARTIS AG (NVS) is classified in the Health Care sector. Its industry is Major Pharmaceutical Manufacturers. It trades on NYSE.
Does NVS pay a dividend?
Yes — NOVARTIS AG (NVS) pays a dividend, with an indicated yield of about 3.40% (market data, as of 2026-09-03). Informational only — not financial advice.
Who are NOVARTIS AG's (NVS) competitors?
Notable peers of NOVARTIS AG (NVS) include Roche, Pfizer, Merck & Co., Bristol Myers Squibb and AstraZeneca. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in NVS?
Yes — we hold 12 matched STOCK Act disclosures for NVS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is NOVARTIS AG (NVS) overbought or oversold right now?
NOVARTIS AG (NVS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.